Genedrive Share Discussion Threads

[milanr] 22/6/2022 08:48

Yes and after 2 years GDR will start selling thousands of POC machines, do you believe it ?

[maxplus2] 21/6/2022 21:47

https://amp.theguardian.com/world/2022/jun/21/covid-surges-europe-ba4-ba5-cases

[milanr] 21/6/2022 12:57

More less 50% down for this period . WHY ?

[milanr] 21/6/2022 12:56

From 02/04 , today is 21/06. Wonder why the share price keeps dripping down.

[snowy20] 21/6/2022 12:46

Let this news rip ,Time to go back to a Quid

[milanr] 21/6/2022 12:44

This machine was driven for free, great results , brilliant machine, unfortunately ZERO sales

[snowy20] 21/6/2022 12:28

Never in this position where NHS released this
Around 300 nurses are being trained to use the machine across MFT at Saint Mary’s Hospital, Wythenshawe Hospital, and North Manchester General Hospital, and the test is expected to be routinely used in all the hospitals’ neonatal units within weeks, which are part of Saint Mary’s Managed Clinical Service within the Trust. Is this day the turning point for a move up

[snowy20] 21/6/2022 12:26

Hxxps://genedrive.com

[snowy20] 21/6/2022 12:25

genedrive.comhxxps://genedrive.com

[milanr] 21/6/2022 10:38

Why GDR cannot sell any product ?

[snowy20] 21/6/2022 10:25

NEW Distributor

[snowy20] 21/6/2022 10:03

No big buys this day .

[snowy20] 21/6/2022 09:56

Low Volume .Blue week looking stronger .Buyers wanting in before more news .

[snowy20] 21/6/2022 09:43

› genedriveplc

[snowy20] 21/6/2022 09:31

Professor Dame Sue Hill, Chief Scientific Officer for England and Senior Responsible Officer for Genomics in the NHS, said: “Genomic medicine is transforming healthcare, and this is a powerful example of how genetic testing can now be done extremely quickly and become a vital part of triage – not only in intensive care but across our services.

“It also shows the importance of thinking about how advances in technology can rapidly transform how we use genomics closer to care for our patients.”

Professor Newman, who is Associate Lead, Hearing Health Genomic Solutions at NIHR Manchester Biomedical Research Centre (BRC), said the team had successfully transferred the accuracy of the machine in the lab to working effectively in a ward. At the same time, clinicians adapted quickly to incorporate the test into their routine care for very sick children in the neonatal ward.

The idea for the test came five years ago, and trials started in 2020 with further adaptations and fine-tuning so that the current machine, which is called the Genedrive System, is now fully CE certified to be used in a clinical setting.

Study results were published in JAMA Pediatrics – the top-ranked paediatrics journal in the world – last week.

Backed by £900,000 funding from the National Institute for Health Research (NIHR) and support from the charity Royal National Institute for Deaf People, the Genedrive System, which costs £80 per baby, was developed by Genedrive, a start-up based at the University of Manchester. It was developed in close collaboration with Professor Newman’s team at Manchester Biomedical Research Centre.

[snowy20] 21/6/2022 09:29

Professor Bill Newman, a consultant in genomic medicine at Manchester University NHS Foundation Trust and Professor of Translational Genomic Medicine at the University of Manchester, led the Pharmacogenetics to Avoid Loss of Hearing (PALoH) study.

He said: “I am absolutely thrilled with the success of the study, and that this testing is now going to be used in three of our Trust’s Neonatal Intensive Care Units – it’s actually going to make a real difference so babies are not going to lose their hearing for a preventable reason.

“The trial demonstrated that you can deploy rapid genetic testing in a clinical setting, and that the tests can be carried out within the ‘golden hour’ when severely unwell babies should be treated with antibiotics.”

Following the completion of the ground-breaking study, the NHS Genomic Medicine Service Alliance and the NHS will be exploring how this technology can be launched as part of a clinical service through the NHS Genomic Medicine Service.

Around 300 nurses are being trained to use the machine across MFT at Saint Mary’s Hospital, Wythenshawe Hospital, and North Manchester General Hospital, and the test is expected to be routinely used in all the hospitals’ neonatal units within weeks, which are part of Saint Mary’s Managed Clinical Service within the Trust.

[snowy20] 21/6/2022 09:27

Never in this position where NHS released this

Around 300 nurses are being trained to use the machine across MFT at Saint Mary’s Hospital, Wythenshawe Hospital, and North Manchester General Hospital, and the test is expected to be routinely used in all the hospitals’ neonatal units within weeks, which are part of Saint Mary’s Managed Clinical Service within the Trust.



Is this day the turning point for a move up

[snowy20] 20/6/2022 13:54

Again buy showing as sell .

[snowy20] 20/6/2022 12:51

60k buy .Buyer did not wait for 18p price that different posters said to wait for

[snowy20] 20/6/2022 12:48

bought in 20S .posters who said to wait to 18p before buying look to have better judgement . if RNS this day not complain .

[snowy20] 20/6/2022 12:48

Never in this position where NHS released this

Around 300 nurses are being trained to use the machine across MFT at Saint Mary’s Hospital, Wythenshawe Hospital, and North Manchester General Hospital, and the test is expected to be routinely used in all the hospitals’ neonatal units within weeks, which are part of Saint Mary’s Managed Clinical Service within the Trust.



Is this day the turning point for a move up

[snowy20] 20/6/2022 12:47

Well financed this year. approx £6 million in bank number months past. NHS AIHL RNS even this week or soon ,Good chance Back to £1 ,50K buyer buying so many shares

[boysie72] 20/6/2022 12:35

And another thicko of society who solely goes round bashing stocks. Filtered

[oilandgasman1] 20/6/2022 12:27

Gdr is a waste of spAce